Roundhill Investments - GLP-1 & Weight Loss ETF

Frequently Asked Questions About OZEM

What does OZEM invest in?

Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.

What is the expense ratio of OZEM?

Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) charges an expense ratio of 0.59%. This is the annual fee deducted from fund assets to cover management and operations.

How big is OZEM?

Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) manages $59.2M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is OZEM actively managed or an index fund?

OZEM is actively managed — the manager selects holdings rather than tracking an index. Active funds typically charge higher expense ratios than index funds (OZEM's is 0.59%) in exchange for the discretion to over- or under-weight positions.

When was OZEM launched?

Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) launched in May 2024 and is managed by Roundhill Investments.

How has OZEM performed?

OZEM's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.